Romosozumab-aqqg is approved for treatment of osteoporosis in postmenopausal women at high risk for fracture defined as: history of osteoporotic fracture, multiple risk factors for fracture, and patients who have failed or are intolerant to other available osteoporosis therapy.
Romosozumab-aqqg is a humanized monoclonal antibody (IgG2) produced in a mammalian cell line
by recombinant DNA technology that binds to and inhibits sclerostin.
Romosozumab-aqqg is should be administered by a healthcare provider. Two separate subcutaneous injections, injected one after the other, are needed to administer the total dose of 210 mg. Injections should be administered once every month for 12 doses in the abdomen, thigh or upper arm.
The anabolic effect of Romosozumab-aqqg wanes after 12 monthly doses of therapy; therefore, you should limit use to 12 monthly doses. If osteoporosis therapy remains warranted, you should consider continued therapy with an anti-resorptive agent.